S
Suzhou Junji Biotechnology
Automating biotech to accelerate life science breakthroughs
About Suzhou Junji Biotechnology
GentleGen is an innovative biotechnology company headquartered in Suzhou, China, focused on advancing life-science research through highly automated, intelligent genetic technology solutions. The company has built a comprehensive, one-stop gene service platform that integrates automation, robotics, and advanced bioengineering to support a wide range of applications, including gene synthesis, oligonucleotide synthesis, Sanger and next-generation sequencing, gene editing, protein expression, and recombinant antibody development. By combining cutting-edge hardware with software-driven workflows, GentleGen enables researchers and biopharmaceutical companies to accelerate discovery, improve experimental reliability, and significantly reduce development timelines. Beyond its core gene services, GentleGen has developed a robust biopharmaceutical safety evaluation system that supports the research and development of nucleic acid drugs, cell and gene therapies, and protein-based therapeutics. This system helps ensure high standards of quality, safety, and compliance from early-stage research through preclinical and clinical development. GentleGen’s solutions are widely adopted by leading research institutions, pharmaceutical companies, and biotechnology enterprises, with its work cited across internationally recognized scientific publications. Driven by a commitment to technological innovation and global health advancement, GentleGen continues to expand its intellectual property portfolio and strengthen strategic partnerships worldwide. Through automation, precision, and scalability, the company aims to reshape how genetic research is conducted—empowering scientists to focus on discovery while GentleGen delivers the infrastructure that makes modern life-science innovation faster, safer, and more efficient.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 50.9/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotechnology, Genetics and genomics, Synthetic Biology, Biotech and Pharma, biotech medtech and e-health, DT and LS, science-based
- Technology
- Artificial Intelligence
- Business model
- Manufacturing, SaaS
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2025 | $14M | $55M | Wuhan Optics Valley Industrial Investment · Tianhui Capital · Lianyungang Jinhai Venture Capital · Jinqiao Fund | ↗ |
| SEED✓Equity / VC | Apr 2024 | $2.8M | $11M | Mingxi Capital | ↗ |
Growth signals
Latest recorded traffic for Suzhou Junji Biotechnology is 170 monthly website visits, down 88.7% over the last three months. Suzhou Junji Biotechnology's team grew 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Junji Biotechnology in its local ecosystem
The Suzhou Junji Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- SPSuzhou Wuzhong Biomedical Industrial Park
- OFOriental Fortune
- MCMingxi Capital
Series A4 investors entered at this stage
- WIWuhan Optics Valley Industrial Investment
- TCTianhui Capital
- LCLianyungang Jinhai Venture Capital
- JFJinqiao Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Junji Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Junji Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








